# Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)

> **NCT03878303** · PHASE1 · UNKNOWN · sponsor: **ACEA Therapeutics, Inc.** · enrollment: 32 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** AC0058TA
- **DRUG:** Placebo AC0058TA

## Key facts

- **NCT ID:** NCT03878303
- **Lead sponsor:** ACEA Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-28
- **Primary completion:** 2020-12
- **Final completion:** 2021-12
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2019-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03878303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03878303, "Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03878303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*